CO6331302A2 - INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH CYTOSTATIC ACTION AND ITS USES IN TUMOR THERAPY - Google Patents
INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH CYTOSTATIC ACTION AND ITS USES IN TUMOR THERAPYInfo
- Publication number
- CO6331302A2 CO6331302A2 CO10159623A CO10159623A CO6331302A2 CO 6331302 A2 CO6331302 A2 CO 6331302A2 CO 10159623 A CO10159623 A CO 10159623A CO 10159623 A CO10159623 A CO 10159623A CO 6331302 A2 CO6331302 A2 CO 6331302A2
- Authority
- CO
- Colombia
- Prior art keywords
- receptor
- inhibitors
- egfr
- growth factor
- epidermal growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con inhibidores del receptor del Factor de Crecimiento Epidérmico (EGFR) que se unen al receptor por los dominios I o III bloqueando la unión de los ligandos naturales pero que permiten el equilibrio fisiológico entre las conformaciones inactiva y activa del receptor de tal forma que impiden la señal mítogénica pero la fracción del dominio II de los receptores que están en conformación activa homodimerizan y autofosforilan al receptor desencadenando la cadena de eventos bioquímicos que mantienen la supervivencia de las células. Los autores de esta invención han encontrado que estos inhibidores que reconocen el EGFR por los dominios I o III tienen un efecto citostático y no citotóxico sobre tumores que expresan dicho receptor y representan una ventaja sobre el estado del arte porque los efectos adversos que provocan son menores que los reportados.The present invention relates to Epidermal Growth Factor (EGFR) receptor inhibitors that bind to the receptor by domains I or III blocking the binding of natural ligands but that allow physiological balance between the inactive and active conformations of the receptor. such that they prevent the mytogenic signal but the fraction of domain II of the receptors that are in active conformation homodimerize and autophosphorylate the receptor by triggering the chain of biochemical events that maintain the survival of the cells. The authors of this invention have found that these inhibitors that recognize EGFR by domains I or III have a cytostatic and non-cytotoxic effect on tumors that express said receptor and represent an advantage over the state of the art because the adverse effects they cause are less than reported.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20080117 | 2008-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6331302A2 true CO6331302A2 (en) | 2011-10-20 |
Family
ID=41433718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10159623A CO6331302A2 (en) | 2008-06-20 | 2010-12-20 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH CYTOSTATIC ACTION AND ITS USES IN TUMOR THERAPY |
Country Status (5)
Country | Link |
---|---|
BR (1) | BRPI0914209A2 (en) |
CO (1) | CO6331302A2 (en) |
MX (1) | MX2010014543A (en) |
TW (1) | TWI500630B (en) |
WO (1) | WO2009152783A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
CU23612A1 (en) * | 2006-09-29 | 2010-12-08 | Centro Inmunologia Molecular | THERAPEUTIC COMBINATIONS TO ENHANCE THE EFFECT OF THERAPY WITH ANTIBODIES AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR |
-
2009
- 2009-06-22 MX MX2010014543A patent/MX2010014543A/en not_active Application Discontinuation
- 2009-06-22 TW TW098120870A patent/TWI500630B/en not_active IP Right Cessation
- 2009-06-22 WO PCT/CU2009/000004 patent/WO2009152783A1/en active Application Filing
- 2009-06-22 BR BRPI0914209A patent/BRPI0914209A2/en not_active IP Right Cessation
-
2010
- 2010-12-20 CO CO10159623A patent/CO6331302A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2010014543A (en) | 2011-04-05 |
WO2009152783A1 (en) | 2009-12-23 |
TWI500630B (en) | 2015-09-21 |
BRPI0914209A2 (en) | 2015-11-03 |
TW201011046A (en) | 2010-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121120T1 (en) | Aryl- or heteroaryl-substituted benzene compounds | |
GT201100017A (en) | PIRIDAZINE DERIVATIVES AS SMO INHIBITORS | |
UY32085A (en) | KINASE INHIBITORS AND METHODS FOR USE | |
AR054566A1 (en) | TREATMENT OF THE TUMORS THAT EXPRESS THE HER | |
CO6741228A2 (en) | Neprilysin Inhibitors | |
UY32455A (en) | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT, AND ITS USES IN THERAPY | |
BR112016012794A2 (en) | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | |
GT201400057A (en) | 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF THE MUTANT HDI | |
ES2571235T3 (en) | Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody | |
CO6351742A2 (en) | ORGANIC COMPOUNDS FOR WOUND CICATRIZATION | |
UY29250A1 (en) | CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.- | |
ECSP099553A (en) | TRICICLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE GLUCOCORTICOSTEROID RECEIVER | |
UY28941A1 (en) | REPLACED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURE AND ITS USE | |
DOP2012000314A (en) | COMPOUNDS, THIOCETATE COMPOSITIONS AND METHODS OF USE | |
ECSP088152A (en) | 7-AZA-SUBSTITUTED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE | |
DK1764372T3 (en) | Tissue inhibitor of metalloproteinases (TIMP) bound to glycosylphosphatidylinositol (GPI) anchors for cancer treatment | |
CO6721010A2 (en) | Mdm2 antagonists of spiro-oxindole | |
GT200800202A (en) | QUINAZOLINS FOR THE INHIBITION OF PDK1 | |
ECSP099376A (en) | AKT ACTIVITY INHIBITORS | |
SV2009003235A (en) | BICYCLE TRIAZOLS AS MODULATORS OF PROTEIN CINASA REF. X-18476M | |
ECSP088221A (en) | ALFA2C ADRENORECEPTORS AGONISTS | |
CR20110353A (en) | THYZOLOPIRIDINE COMPOUNDS SIRTUINE MODULATORS CROSSED REFERENCE | |
UY29249A1 (en) | CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANS | |
ECSP10010361A (en) | DERIVATIVES OF PIRIDAZINONA | |
GT200600253A (en) | AMINOPIRIMIDINS AS KINASE MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |